Severe Aplastic Anaemia Working Party (SAAWP)
Study type:
Study number:
84090094
Type of Stem Cell Treatment:
Allogeneic
Diseases:
Bone marrow failure
Short title:
Allo HCT for ERCC6L2
Primary objective:
We aim to investigate detailed characteristics and outcomes of patients with biallelic germline mutations in ERCC6L2 who undergo allogeneic-HSCT. In addition, we aspire to explore comprehensive diagnostics and treatment strategies in evaluation of the timing of allogeneic-HSCT for patients with ERCC6L2 mutations.
Key inclusion criteria:
Country:
All EBMT member countries
Principal investigator:
Ulla Wartiovaara-Kautto, Outi Kilpivaara and Flore Sicre de Fontbrune
EBMT Study coordinator:
Brian Piepenbroek
Study coordinator email:
saawpebmt@lumc.nl
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Not applicable to surveys
Categories of personal data collected:
Not applicable to surveys
Recipients who may access the data:
Not applicable to surveys
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
Not applicable to surveys
Privacy notices
Article 6 lawful basis for processing personal data:
Not applicable to surveys
Article 9 basis for processing special category data:
Not applicable to surveys
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
Not applicable to surveys
Retention Schedule (if possible):
Not applicable to surveys